5LAW OFFICES

KILYK & BOWERSOX, P.L.L.C.

RECEIVED **CENTRAL FAX CENTER**

APR 0 9 2007

Intellectual Property Law

From the Desk of LUKE A. KILYK*

400 Holiday Court Suite 102 WARRENTON, VA 20186

FAIRFAX OFFICE 3603-E Chain Bridge Road Fairfax, Virginia 22030

Email: [kilyk@kbpatentlaw.com Website: http://www.kbpatentlaw.com

TEL.: (540) 428-1701

FAC.:

(540) 428-1720

*Admitted only in PA and DC

(540) 428-1721

PLEASE DIRECT CORRESPONDENCE TO OUR WARRENTON OFFICE

FACSIMILE TRANSMISSION COVER SHEET

DATE:

April 9, 2007

5404281721

TO:

Group Art Unit: 1645 Mail Stop Amendment Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

RE:

U.S. Patent Application No. 10/577,791

Entitled: Dose-Dependent Promoter Originating in Humans

Our Ref.: 3190-094

FROM:

Luke A. Kilyk, Esq223

FAC. TEL. NO.:

1-571-273-8300

NUMBER OF PAGES (INCLUDING THIS COVER SHEET):

Items Attached: Second Supplemental Information Disclosure Statement -- 3 pages

Form PTO/SB/08 -- 2 pages Cited Documents – 7 pages

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on April 9, 2007.

<u>Kim Blum</u> Name (Print)

THE INFORMATION CONTAINED IN THIS MESSAGE IS CONFIDENTIAL INFORMATION INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED. This message may also be an attorney/client communication which is privileged and confidential. If the reader of this message is not the intended recipient, or the employee or agent responsible to deliver it to the intended recipient, you are hereby notified that any distribution or copying of this communication is strictly prohibited. If you have received this communication in error, please notify us immediately by calling us collect and return the original message to us at the above address by mail. Thank you.

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office, Fax No. 1-571-273-8300 on April 9, 2007.

Kim Blum
Name (Print)
Signature

5404281721

RECEIVED
CENTRAL FAX CENTER

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE APR 0 9 2007

In re Application of: YOKOTA et al.

Application Number: 10/577,791

Filed:

April 28, 2006

Docket No.:

3190-094

Examiner:

Group Art Unit: 1645

Confirmation No.: 9745

Customer No.: 33432

For: Dose-Dependent Promoter Originating in Humans

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT PURSUANT TO 37 CFR 1.97(c)

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

April 9, 2007

Sir:

The attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached Form PTO-SB-08. Pursuant to the current United States Patent and Trademark Office rules, no copies of U.S. Patents/Patent Application Publications are provided.

This Second Supplemental Information Disclosure Statement is being submitted after expiration of the three-month period following filing of the above-captioned application but before any Final Office Action or Notice of Allowance.

The undersigned hereby certifies that each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement.

Second Supplemental Information Disclosure Statement U.S. Patent Application No. 10/577,791

The above information is presented so that the Patent and Trademark Office can, in the first instance, determine any materiality thereof to the claimed invention. See 37 CFR 1.104(a) and 1.106(b) concerning the PTO duty to consider and use any such information. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents cited in the attached Form PTO-SB-08 be made of record therein and appear on the first page of any patent to issue therefrom.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in this application and applicant determines that the cited documents do not constitute "prior art" under United States law, applicant reserves the right to present to the office the relevant facts and law regarding the appropriate status of such documents.

Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

It is believed that no fee is required to make this a complete and timely filing. However, if it is determined that a petition or fee is required, the Commissioner is hereby authorized to charge any fee associated with this statement to our Deposit Account No. 50-0925.

Respectfully submitted,

Luke A. Kilyk

Keg. No. 33,231

Second Supplemental Information Disclosure Statement U.S. Patent Application No. 10/577,791

Atty. Docket No.: 3190-094 KILYK & BOWERSOX, P.L.L.C. 400 Holiday Court, Suite 102 Warrenton, VA 20186 Tel: (540) 428-1701

Tel: (540) 428-1701 Fax: (540) 428-1720

Enclosures: PTO/SB/08 w/4 Documents

RECEIVED CENTRAL FAX CENTER

APR 0 9 2007 TO/SB/088 (09-0)

Approved for use through	19/31/2007 /34D 00E4 000
11 0 Batan and Topico de la care direction	03/3 1/2007. CMAD 003 1-003
U.S. Patent and Trademark Office; U.S. DE	PARTMENT OF COMMERCI
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of Information unless it display	THE PARTY OF COMMENCE
the parasits are required to respond to a collection of information unless it display	S & VAND OMPL control numbe

Substitute for form 1449A/PTO				Complete If Known		
				Application Number	10/577,791	
1	NFORMATION DIS	SCLOSI	IRF	Filing Date	April 28, 2006	
STATEMENT BY APPLICANT				First Named Inventor	YOKOTA et al.	
•	STATEMENT DE APPLICANT			Art Unit	1645	
(Use as many sheets as necessary)				Examiner Name	Unassigned	
Sheet	1	of	2	Attorney Docket Number	3190-094	

U.S. PATENT OCCUMENTS						
Examiner	Cite	Cite Document Number No. Number - Kind Code ^{2 (* Ampun)}	Publication Date MM-DD-YYYY	Name of Patentee or	Pages, Columns, Lines, Where	
Initials*	No.1			Applicant of Cited Document	Relevant Passages or Relevant Figures Appear	
		US-6,783,961 B1	08-31-2004	Edwards et al.		
		US-7,115,416 B1	10-03-2006	Edwards et al.		
		US-				
		US-			· · · · · · · · · · · · · · · · · · ·	
		US-				
		US-				
		US-				
		US-				
		US-				
		US-				
		us-				
		US-				
		US-			** **** **** **** **** **** **** **** ****	
		U\$-	************************************		,	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No.	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages	٦,
		Country Code ³ - Number ⁴ - Kind Code ³ (if known) JP2001289182	10-02-2001	Genset S.A.	or Relevant Figures Appear English Abstract attached; See	H
					U.S. Patent Nos. 6,783,981 B1 and 7,115,416 B1 for U.S. equivalents.	
						┖
	<u> </u>					Г
	<u> </u>		<u> </u>			С
]	L.M.

	 T	T	
Examiner	Date	1	
	1	1	
Signature	Considered		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹Applicant's unique citation designation number (optional). ²See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 97 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

2

3190-094

PTO/SB/08b (09-06)
Approved for use through 03/31/2007. OMB 0651-0031
U.S. Patient and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Substitute for form 14498/PTO Complete if Known Application Number 10/577,791 RECEIVED INFORMATION DISCLOSURE Filing Date April 28, 2008 CENTRAL First Named Inventor YOKOTA et al STATEMENT BY APPLICANT Art Unit 1645 APR (Use as many sheets as necessary) Examiner Name Unassigned Sheet

Attorney Docket Number

NON PATENT LITERATURE DOCUMENTS						
Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	7			
		Supplementary Partial European Search Report for corresponding European Patent Application No. EP 04 79 3208 dated February 23, 2007				
		Database EMBL, "5' EST and human protein encoded thereby," XP002419364, retrieved from EBI Accession No. EM_PRO:BD204430, Abstract, August 13, 2003 (2 pages).				
		Database EMBL, "Sequence tag and encoded human protein," XP002419385, retrieved from EBI Accession No. EM_PRO:BD034334, Abstract, September 4, 2002 (1 page).				

Examiner	Date	
Signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete. including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTQ-9199 and select option 2.